...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers.
【24h】

Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers.

机译：在健康的男性和女性志愿者中，美洛昔康不影响阿司匹林的抗血小板作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study determined if meloxicam, a selective cyclooxygenase (COX)-2 inhibitor, interferes with the antiplatelet effect of aspirin using platelet aggregation and thromboxane (Tx) B(2) endpoints in healthy volunteers. Eight male and 8 female volunteers participated in this open-label, randomized, two-treatment, two-way crossover trial. Treatment 1 was meloxicam (15 mg qd) over 4 days, and then aspirin (100 mg qd) was ingested 2 hours after meloxicam for an additional 7 days. Blood samples were taken 2, 6, and 24 hours after the last dose. Treatment 2 consisted of only aspirin (100 mg) over 2 days. Samples were taken at the same time points. Each subject received both treatments with a 2-week washout between the treatment periods. Treatments were safe and well tolerated. The initial 4-day treatment with meloxicam had no effect on platelet aggregation but reduced serum TxB(2) by 64% +/- 19%. Addition of aspirin (100 mg qd) for 7 days resulted in complete inhibition of aggregation and TxB(2) for 24 hours. Two-day treatment with only 100 mg aspirin also resulted in complete inhibition of platelet aggregation and TxB(2). These results indicate that meloxicam does not affect the ability of aspirin to inhibit COX-1 in platelets, thereby allowing aspirin to effectively prevent platelet aggregation and reduce TxB(2) levels, and that meloxicam is selective for COX-2.
机译：这项研究确定了是否在健康志愿者中使用血小板聚集和血栓烷（Tx）B（2）终点美洛昔康（一种选择性的环氧合酶（COX）-2抑制剂）干扰了阿司匹林的抗血小板作用。八名男性和八名女性志愿者参加了这项开放标签，随机，两次治疗，两次交叉试验。处理1为美洛昔康（15 mg qd），历时4天，然后在美洛昔康2小时后再摄取阿司匹林（100 mg qd），持续7天。在最后一次给药后2、6和24小时采集血样。治疗2在2天内仅包含阿司匹林（100 mg）。在相同的时间点取样。每个受试者都接受了两种治疗，并且在治疗期间之间进行了2周的冲洗。治疗安全且耐受良好。初始用美洛昔康治疗4天对血小板聚集没有影响，但血清TxB（2）降低了64％+/- 19％。加入阿司匹林（100 mg qd）7天导致24小时完全抑制聚集和TxB（2）。仅使用100毫克阿司匹林的两天治疗也导致血小板聚集和TxB（2）的完全抑制。这些结果表明，美洛昔康不影响阿司匹林抑制血小板中COX-1的能力，从而使阿司匹林有效防止血小板凝集并降低TxB（2）的水平，并且美洛昔康对COX-2具有选择性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号